Injection of vascular endothelial growth factor into knee joints induces osteoarthritis in mice  by Ludin, A. et al.
Osteoarthritis and Cartilage 21 (2013) 491e497Injection of vascular endothelial growth factor into knee joints induces
osteoarthritis in miceA. Ludin yza, J.J. Sela x*, A. Schroeder k, Y. Samuni z, D.W. Nitzan z, G. Amir{
yDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel
zDepartment of Oral and Maxillofacial Surgery, Hebrew University Hadassah-Faculty of Dental Medicine, Jerusalem, Israel
x Institute of Dental Sciences, Hebrew University Hadassah-Faculty of Dental Medicine, Jerusalem, Israel
kDepartment of Chemical Engineering, Technion e Israel Institute of Technology, Haifa, Israel
{Department of Pathology, Hebrew University-Hadassah Medical Center, Jerusalem, Israela r t i c l e i n f o
Article history:
Received 6 September 2012
Accepted 7 December 2012
Keywords:
Vascular endothelial growth factor
VEGF
Mice
Intra-articular injection
Osteoarthritis
Synovial hyperplasia
Cartilage degeneration* Address correspondence and reprint requests
and Dental Medicine, Laboratory of Biomineralization
The Hebrew University Hadassah-Faculty of Denta
Jerusalem 91120, Israel. Tel: 972-2-6758576; Fax: 972
E-mail address: jjsela@cc.huji.ac.il (J.J. Sela).
URL: http://dental.huji.ac.il:80/newEsite/departme
a MSc Thesis.
1063-4584/$ e see front matter  2012 Osteoarthriti
http://dx.doi.org/10.1016/j.joca.2012.12.003s u m m a r y
Osteoarthritis (OA) is a common joint disorder affecting circa 2% of the population.
Objectives: It has been suggested that secretion of vascular endothelial growth factor (VEGF) could play
a role in the chain of events leading to OA.
Methods: In the present study, healthy mice were injected intra-articularly with VEGF.
Results: Shortly after the administration of VEGF, synovial hyperplasia, increased calciﬁcation of the
articular cartilage and bone sclerosis were observed. Consequently, cartilage degradation characteristic of
OA was found. These changes were seen to a lesser degree in the opposite knees of VEGF-injected mice
and did not occur in the control mice.
Conclusions: The ﬁndings suggest an active role of VEGF in the pathogenesis of OA and render support to
a possible role for subchondral bone sclerosis in the pathogenesis of cartilage degradation.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a prevalent, slowly progressing joint
disorder clinically manifested by pain and disability. OA is charac-
terized by synovitis, cartilage degeneration, subchondral bone
sclerosis, and osteophyte formation. Articular cartilage degradation
is a hallmark of OA. It should be pointed out that changes in the
subchondral bone play a major role in the onset and progression of
the disease1e3. Initiation of OA has been correlated with either
excessive or alternatively, insufﬁcient blood ﬂow to the sub-
chondral bone4. The latter may be associated with compromised
delivery of nutrients and gas exchange with the articular cartilage5.
In OA, osteoclastic resorption of the subchondral bone is fol-
lowed by reduction of structural support to the articular cartilage6,7.
Sclerosis associated contour changes result with a decrease in the
mechanical, shock-absorbing support produced by the cartilage1.to: J.J. Sela, Oral Pathology
, Institute of Dental Sciences,
l Medicine, P.O. Box 12272,
-2-6424144.
nts/institute/jsela.htm
s Research Society International. PThe damage to the articular cartilage is accompanied by de-novo
formation of blood capillaries, initiation of osteophyte formation
and calciﬁcation of the articular cartilage. Blood vessel formation
may be accompanied by pro-apoptotic factors that lead to chon-
drocytic death8. In the synovial membrane, new vasculature could
be responsible for edema and promotion of an inﬂammatory
process9 which among its other effects compromise joint lubrica-
tion10. Vascular endothelial growth factor (VEGF) is expressed in
synoviocytes10, macrophages11 and in chondrocytes in human
osteoarthritic joints12. VEGF has been shown to affect chondrocytic
proliferation, apoptosis, and metabolism, leading to release of
metalloproteinases (MMPs), as well as other catabolic mediators
that degrade the cartilage matrix13e15. VEGF is expressed in the
superﬁcial zone of the cartilage disc, and has been shown to be
secreted from mechanically overloaded chondrocytes13 and in OA
joints in vivo16. Another study showed that synovial ﬂuid sourced
from OA patients had 20-fold higher concentrations of VEGF in
comparison to its level in healthy joints, thereby suggesting that
VEGF takes part in OA development17.
The present is a study of the effect of intra-articular injection, of
exogenous VEGF, on mice knee joints. The histo-morphological
structure of the joints was evaluated and graded at the cellular
and structural levels. OA grading of the cartilage, subchondral
calciﬁed tissues, and synovial membrane was performed.ublished by Elsevier Ltd. All rights reserved.
Table I
Histological scoring
Finding Grade
Structure Normal 0
Slight surface irregularity 1
Fibrillation reaching zones 1e2 2
Fibrillation reaching zone 3 3
Fibrillation reaching zone 4 4
Cracks (near the tidemark) 5
Erosion of zones 1e3 6
Erosion of zone 4 7
Exposed bone 8
Cluster appearance Normal 0
Cluster appearance 2
Tidemark Intact 0
Multiple 1
Indistinct 2
Crossed by blood vessels 3
None 0
Osteophyte formation Cartilage increment 1
Early osteophytes 2
Developed osteophytes 4
Subchondral bone Normal 0
Sclerosis 1
Synovial membrane Normal 0
Hyperplasia e mild 1
Hyperplasia involving half the synovial
space
2
Hyperplasia involving the entire synovial
space
3
Safranin-O staining Strong staining of the cartilage 0
Slight reduction 1
Moderate reduction 2
Severe reduction 3
No stain 4
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Animals
This study was approved and conducted according to the
guidelines of the Hebrew University Animal Healthcare Ethics
Committee.
Male ICR (CD-1) mice 8e10-weeks-old (Harlan, Israel) were
used. The mice were held in speciﬁc pathogen free (SPF) conditions
at the Hebrew University Ein Kerem animal facility and were given
access to conventional chow and tap water ad libitum.
Materials
Recombinant murine VEGF165 (PeproTec, Rocky hill, NJ, USA)
was dissolved in physiological saline (Teva, Israel) to reach
a concentration of 0.05 mg/ml.
Experimental design
The experimental group consisted mice that received intra-
articular injections, to the synovial space (see injection procedure
below), of 20 ml VEGF165 solution once a week over a period of
4 weeks. Mice were sacriﬁced 1,2,3,4,6 and 8 weeks post-ﬁrst
injection, 10 mice per time point. The effect of VEGF on OA devel-
opment was examined by histological evaluation. In the control
groups, 10 mice were not subjected to any kind of treatment (sham
group) and 20 mice received one intra-articular injection of 20 ml
of physiological saline (0.9% NaCl, Pharmaceutics Department,
Hadassah Medical Center, Jerusalem, Israel) and were sacriﬁced 2
and 8 weeks after injection, 10 mice at each time point.
VEGF administration
Mice were anesthetized using a 0.15 ml Xylazine 2% and 0.85 ml
Ketamine HCl injected intra-peritoneally (i.p.). Then the left rear
knee of each mouse was shaved and the patellar ligament was
exposed to allow an approach from the lateral side of the knee,
using a syringe equipped with a 27 gauge needle. The needle was
inserted beneath the patellar ligament, into the intra-articular
space and a volume of 20 ml solution containing either saline, or
VEGF was introduced.
Tissue analysis
At the above-described time points, mice were sacriﬁced with
an overdose of the anesthesia solution injected i.p. Their rear left
(injected) and right (non-injected) knees were removed, ﬁxed in
buffered formaldehyde, decalciﬁed with a calcium-chelating agent
(Calci-Clear Rapid, National Diagnostics, Atlanta, Georgia, USA), and
embedded in parafﬁn. Sections, 6 mm thick, were cut and stained
with either Hematoxylin & Eosin (H&E) or Safranin-O, according to
the standard protocols (see below). The lateral and medial aspects
of both the distal femoral bones and the proximal tibial bones,
separated by the cruciate ligament, were examined separately.
Pathological changes observed in each of the four aspects of the
knee joint were graded, according to a score shown in Table I, based
on the Mankin score, and modiﬁed to include bone sclerosis.
Imunohistochemical staining of VEGF
Imunohistochemical staining of VEGF was performed on three
representative knees, with scores typical for their sacriﬁce date,
selected from each of the control and VEGF groups. Imunohis-
tochemical staining was performed on formalin-ﬁxed, parafﬁn-embedded bone sections, using the avidinebiotineperoxidase
complex method using horseradish peroxidase (HRPO)-labeled
anti-mouse immuno-globulin (HistoﬁneSimple Stain Souse MAX-
PO, Nichirei Biosciences Inc., Tokyo, Japan) and Diaminobenzidine
substrate (SIGMA FAST 3,30-Diaminobenzidine tablets, Sigma,
Rehovot, Israel). Non-speciﬁc staining was avoided using incuba-
tion in 30% H2O2 to deactivate endogenous peroxidase and using
M.O.MT.M kit (Vector Inc. Burlingame, CA, USA) according to
the manufacturer instructions. VEGF staining was performed
using monoclonal murine anti-human VEGF antibody (1:25 dilu-
tion, DAKO, Copenhagen, Denmark), which recognizes murine
VEGF.
Antigen retrieval was performed by heat treatment of 88C
overnight before deparafﬁnization and incubation for 30 min in
1 mM EDTA (pH 8) after deparafﬁnization. Slides were counter-
stained with Mayer’s Hematoxylin. As a control, the same proce-
dure was performed on a sequential section omitting the anti-VEGF
antibody.
Histo-morphometric analysis
Chondrocytes number was assessed by histo-morphometry. The
stained slides were analyzed using a computerized morphometric
system (WinScanArray3; Galai, Migdal Haemek, Israel) connected
to a light microscope (BH-2; Olympus, Tokyo, Japan). In each slide,
consecutive microscope ﬁelds covering the entire articular cartilage
of the examined knee were acquired (at magniﬁcation 400 and
resolution of 1024  1024) by a color video camera (DXC-151AD;
Sony, Tokyo, Japan). After acquisition, the images underwent
automated light analysis and noise removal procedures to ensure
color and image quality standardization in all analyses. Using PC-
based Image analysis software (ImageProþv4.5, Media Cyber-
netics, USA) the total area (in mm2) of the cartilagewasmeasured by
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chondrocytes were enumerated by assigning a color threshold
using RGB color separation to isolate the chondrocytes nuclei, as
previously described. The isolated nuclei were counted automati-
cally by the “ImagePro” software.
For each image, ratios of chondrocytes number:cartilage area,
giving the number of chondrocytes per 1 mm cartilage, were
calculated using Excel software.
Statistical analysis
Statistical evaluation was performed using SPSS software,
version 12.
The KruskaleWallis nonparametric test was used to compare
more than two groups of variables. Signiﬁcance was set at P  0.05.
When differences were found, the ManneWhitney nonparametric
test was used to conﬁrm signiﬁcant differences between
two groups of variables, using the Bonferroni correction to set P-
values.
Results
Progressive osteoarthritic changes were noted in all the joint
tissues of the VEGF-treated animals, portraying a sequence of OA
progression.
Tidemark multiplication
Changes in tidemark appearance are shown in Fig. 1(A) as
mean number  SE. Tidemark alterations, indicating cartilageFig. 1. Changes in the calciﬁed tissues following VEGF injections. Following VEGF injectio
section of: (B) right tibial condyle of VEGF injected knee after 4 weeks showing multiple tid
bone sclerosis beneath a thinned layer of articular cartilage.
Values are of mean scores  95% conﬁdence interval. For scoring values see Table I. *A: P ¼calciﬁcation, began 1 week after VEGF injection in nine (out of 10)
knees. By the 4th week [Fig. 1(B)], tidemark multiplications were
observed in almost all aspects of the knee in seven (out of eight)
knees. This is opposed to both control groups, in which only a sin-
gle tidemark or occasionally two tidemarks were noticed. The
appearance of such a limited number of tidemarks in the control
groups is considered normal.
Subchondral bone sclerosis
Marked sclerosis was observed in the early weeks of the
experiment and is presented in Fig. 1(C) as mean score  SE. In the
2nd and 3rd weeks following VEGF injections sclerosis was
observed in eight (out of 10) and 10 (out of 10) knees, respectively,
involving themedial and lateral sides of both tibias and femurs. The
frequency and severity of subchondral sclerosis declined 21 days
post the VEGF injection. The disappearance of the sclerosis suggests
that the subchondral bone has the potential to remodel once the
cause (i.e., VEGF) is eliminated.
At week 4, none of the mice demonstrated sclerosis; and at that
time VEGF was detected in the endothelial lining of the sinuses and
in osteoblasts of the trabecular bone [Fig. 4(D)]. By week 6, sub-
chondral sclerosis was detected in only three (out of eight) knees.
Sclerosis, indicated by slight diminution of the marrow space, was
rarely observed in the control groups [Fig. 1(C)].
Osteophyte formation
In this study osteophyte formation was rarely observed. In mice
receiving weekly VEGF injections, osteophytes were observed onlyns alterations in the tidemark (A), and in bone sclerosis (C), were evident. Histological
emarks (arrows), and of the (D) right femoral condyle of VEGF injected knee showing
0.0054; B: P ¼ 0.042.
Fig. 2. Cartilage alterations following VEGF injections. (A) Cartilage morphological changes over 8 weeks. (B) Erosion of the articular cartilage, after 8 weeks, in a VEGF injected
left femoral condyle. (C) Mean cell number per 1 mm cartilage SE, presenting cellularity rate over 8 weeks of the experiment. (D) Safranin-O stain score over 8 weeks, where higher
score designates loss of stain. (E) Left femoral condyle of VEGF injected knee after 6 weeks stained for Safranin-O presenting loss of stain in the cartilage. The area in the rectangle is
enlarged on the right showing loss of staining where the articular cartilage is left. Values are of mean scores  95% conﬁdence interval.
For scoring values see Table I. A: P ¼ 0.039; C: P ¼ 0.0047; D: P ¼ 0.0002. HC, hyaline cartilage; CC, calciﬁed cartilage.
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osteophytes were found.
Hyaline cartilage degradation
In both sham- and saline-injected control groups cartilage was
generally intact; occasionally mild surface irregularities were
noticed.
On the other hand, the cartilage of mice receiving VEGF injec-
tions on a weekly basis underwent progressive degradation, which
was most severe at the 6th and 8th weeks [Fig. 2(A) and (B)].
Between the 1st and 4th weeks after the ﬁrst injection, no alter-
ations or mild irregularities (grade 1) were found in the injected
knees. Interestingly, during the 3rd week, VEGF was observed in
chondrocytes in the superﬁcial layer of the articular cartilage
[Fig. 4(C)]. However, 6 weeks after initiation of treatment (2 weeks
after the last injection), six out of eight knees demonstrated severe
erosion, and at week 8, ﬁve (out of eight) knees had extensive
ﬁbrillation and erosion.Cartilage cellularity
Changes in cartilage cellularity, measured by histo-morphometry,
are shown in Fig. 2(C) as mean number  SE of cartilage cellularity
ratio.
Cartilage cellularity ratios measured for the sham- and saline-
injected control groups were 0.25 and 0.3 cells per 1 mm carti-
lage, respectively. In mice receiving weekly VEGF injections, 2 or 3
weeks after the onset of treatment chondrocytic ratios were
signiﬁcantly elevated (ratio of 0.41 and 0.42 cells per 1 mm cartilage,
respectively). However, chondrocytic numbers declined to baseline
levels by week 8.
Cartilage mucopolysaccharide loss
Gradual decrease in Safranin-O staining, indicating mucopoly-
saccharide loss, was observed in the cartilage of treated knee joints
[Fig. 2(D)]. Knee joints from sham controls showed no alterations in
mucopolysaccharide content. The saline injected knees showed
Fig. 3. Synovial alterations following VEGF injections. (A) Synovial changes over 8 weeks. (B) VEGF immunostaining of synovial membrane near the left tibial condyle in VEGF
injected knee after 4 weeks showing vascular hypertrophy and staining of large blood vessels for VEGF. (C) Control (secondary antibody only) and (D) Immunostaining of VEGF of
the synovial membrane of a right tibial condyle after 3 weeks, showing marked cytoplasmatic staining of synoviocytes (rectangle enlarged at the bottom) in the stained specimen.
Values are of mean scores  95% interval.
For scoring values see Table I. A: *P ¼ 0.013.
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mucopolysaccharides was observed after weekly injections of
VEGF.
By weeks 4 and 6, complete mucopolysaccharide loss was
observed in all specimens [Fig. 2(D) and (E)].
Synovial membrane hyperplasia
Synovial membrane hyperplasia, detected on H&E stained
sections, increased after VEGF injections and declined over time
when VEGF was not injected.
These changes are presented in Fig. 3(A) as mean score þSE.
Synovial membrane hyperplasia was accompanied by the appear-
ance of prominent blood vessels in the joint capsule [Fig. 3(B)]. In
both control groups, the synovial membrane consisted of 1e2 cells
thick cellular layer.
Following weekly injections of VEGF, synovial hyperplasia was
observed at weeks 2 and 3 after the primary injection in eight (out
of 10) and nine (out of 10) knees, respectively. Of these, six (out of
eight) and ﬁve (out of nine) knees showed synovial hyperplasia in
both medial and lateral aspects. At this time frame, VEGF was
detected by immune-histochemistry in the synoviocytes [Fig. 3(C)
and (D)]. By week 4 after initiation of treatment all knees examined
showed synovial hyperplastic changes in all joint aspects.
Cessation of VEGF injections on week 4 reduced synovial
hyperplasia, reaching a level of ﬁve/eight knees onweek 8. In these
weeks (i.e., 6 and 8 after treatment initiation), VEGF staining was
conﬁned to synoviocytes and was not observed in other tissues.
Interestingly, the opposing (non-injected) knees of animals
treated by VEGF presented similar changes and arthrosisprogression pattern in cartilage and bone. However, these changes
were less frequent and less severe in comparison to the injected
knee.
VEGF expression in osteoarthritic knees
The presence of VEGF in knees developing OA was detected by
speciﬁc immunostaining. In the healthy mouse VEGF staining was
not detected in the cartilage [Fig. 4(A)], bone [Fig. 4(B)] and syno-
vium [Fig. 1(C)].
Following VEGF injections, VEGF staining ﬁrst appeared after 3
weeks. It was observed in the cytoplasm of synoviocytes [Fig. 3(D)]
and in chondrocytes in the superﬁcial layer of the articular cartilage
[Fig. 4(C)]. At that time, VEGF staining was also observed in the
endothelial lining of the sinuses and in osteoblasts in the trabecular
bone [Fig. 4(D)]. A similar staining pattern was observed in mice
sacriﬁced at week 4. By weeks 6 and 8 after treatment initiation,
VEGF staining was conﬁned to synoviocytes and was not observed
in other tissues.
Discussion
The present study revealed that exogenous VEGF, injected intra-
articularly in healthy mice, initiated a full-range osteoarthritic
process in the knee joint.
The early signs of OA were synovial hyperplasia associated with
an increase in blood vessels quantities. Synovial hyperplasia and
increased vasculature appeared concomitantly with both progres-
sive calciﬁcation in the calciﬁed layer of the articular cartilage,
manifested by tidemark advancement, as well as by subchondral
Fig. 4. Immunostaining of the cartilage and bone of VEGF injected knees. (A) Knee of Sham mouse shows no VEGF staining in the cartilage or (B) cells of the marrow or (C) in the
synovium. (D) After 3 weeks of VEGF injection, chondrocytes of the hyaline cartilage in the injected knees show staining with VEGF (arrows). (D) Osteoblasts and endothelial lining
of the sinuses of the injected knees show staining with VEGF, after 4 weeks of VEGF injection (areas in the rectangle are enlarged on the black marked ﬁgures at the bottom).
HC, hyaline cartilage; CC, Calciﬁed cartilage; OB, osteoblast; E, endothelial cell.
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the cartilage and extension or multiplication of the tidemark
displays a response to injury. These changes were accompanied by
the expression of the effect of VEGF on synoviocytes, osteoblasts,
and endothelial cells in the marrow, and in the third week post-
VEGF administration, on chondrocytes.
On week 6, following ossiﬁcation and remodeling of the sub-
chondral tissue, synovial hyperplastic changes reached their peak
and cartilage degradation became more severe, with deep ﬁbrilla-
tion, erosion of the cartilage, and cracking near the tidemark.
The sequence of events leading to OA following VEGF adminis-
tration shows that the articular cartilage degradation occurred
subsequent to alterations in the synovial and calciﬁed layers. Sub-
chondral bone supports a large portion of the load exerted on the
joint, relative to the overlying hyaline articular cartilage18.
Increasing rigidity of the subchondral tissues reduces absorbing
capacity, thus exposing the cartilage to higher loads that contribute
to its degradation1. VEGF seems to promote calciﬁed cartilageossiﬁcation and subchondral bone remodeling and, as noticed in
the later weeks of the experiment, may play a role in the patho-
genesis of OA.
The expression of VEGF in chondrocytes in the superﬁcial and
mid zones of the hyaline cartilage of the VEGF-injected mice
contrary to the controls suggests a further role for VEGF in the
initiation and progression of OA.
Similar morphologic changes, to a lesser extent and severity,
were observed in the contra lateral non-injected knees. It is
possible that VEGF is absorbed into the circulation giving rise to
systemic effects. Discontinuation of VEGF administration resulted
in resolution of subchondral bone sclerosis and synovial hyper-
plasia. This suggests that consistent VEGF presence in these sites is
required to maintain the alterations. Without VEGF, the possibility
of spontaneous rehabilitation should be considered. The discordant
healing of bone, despite marked cartilage degradation in this
model, may be explained by the lesser ability of cartilage to
regenerate relative to bone. Thus, injuries to the cartilage are
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chondral bone changes before the onset of the degenerative
changes in the articular cartilage suggests the importance of sub-
chondral calcifying tissues in promoting the progression of the
disease.
The notion that impaired angiogenesis and vascular pathology is
associated with OA, has been suggested previously. This study
points to a probable role for VEGF in initiating and propagating OA
ﬁrstly, by activating the synovial and calciﬁed tissues of the joint. It
is possible that VEGF affects the calciﬁed tissues initially by altering
subchondral tissue metabolism and promoting release of factors of
vascular remodeling. These ﬁndings suggest that controlling VEGF
secretion may help to prevent OA escalation and OA-associated
joint deterioration.
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